<DOC>
	<DOCNO>NCT00634660</DOCNO>
	<brief_summary>The purpose study assess safety tolerability injection rAvPAL-PEG subject PKU .</brief_summary>
	<brief_title>Safety Tolerability Study rAvPAL-PEG Treat Phenylketonuria</brief_title>
	<detailed_description>This Phase 1 , open-label , single-dose study approximately 35 subject PKU 16 50 year old . Seven cohort plan , consist 5 subject ; cohort plan 0.001 , 0.003 , 0.01 , 0.03 , 0.1 , 0.3 , 1.0 mg/kg . Increasing dose rAvPAL-PEG assess sequentially final dose evaluate stop criterion reach . Subjects receive single dose follow total 42 day ( 6 week ) visit clinical research unit ( CRU ) specify Schedule Events Toxicity measure accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE , v 3 ) .</detailed_description>
	<mesh_term>Phenylketonurias</mesh_term>
	<criteria>Diagnosis PKU follow : Current blood Phe concentration ≥600 µmol/L Screening . Average blood Phe concentration ≥600 µmol/L past 3 year , use available data . Willing able provide write , sign informed consent , , case participant age 18 , provide write assent ( require ) write informed consent parent legal guardian , nature study explain , prior researchrelated procedure . Willing able comply study procedure . Between age 16 50 year , inclusive . Females childbearing potential must negative pregnancy test Screening willing additional pregnancy test study . Females consider childbearing potential include menopause least 2 year , tubal ligation least 1 year prior Screening , total hysterectomy . Sexually active subject must willing use acceptable method contraception participate study . Stable diet significant modification 4 week precede administration study drug . In generally good health evidence physical examination , clinical laboratory evaluation ( hematology , chemistry , urinalysis ) , electrocardiogram ( ECG ) Screening . Use investigational product investigational medical device within 30 day prior Screening , requirement investigational agent prior completion schedule study assessment . Pregnant breastfeed Screening plan become pregnant ( self partner ) breastfeed time study . Concurrent disease condition would interfere study participation safety ( eg , history presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurological , oncologic , psychiatric disease ) . Any condition , view Principal Investigator ( PI ) , place subject high risk poor treatment compliance complete study . Known hypersensitivity rAvPAL PEG excipients . Alanine aminotransferase ( ALT ) concentration &gt; 2 time upper limit normal . Creatinine upper limit normal . Donation blood plasma within 30 day prior administration study drug . Use overthecounter ( OTC ) medication , include vitamin , within 7 day prior administration study drug , without evaluation approval Investigator . Use prescription medication within 14 day prior administration study drug without evaluation approval Investigator . Treatment drug know affect hepatic enzyme activity , include ( limited ) barbiturate , phenothiazine , cimetidine , carbamazepine , within 30 day prior study drug administration . Use tobacco product within 60 day prior study drug administration . Positive urine screen use nicotine ( cotinine ) drug abuse ( amphetamine , barbiturate , benzodiazepine , cocaine , cannabinoids , opiate ) . Positive test treat hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>